Title Physician

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) (ACTION)

NCT ID : 05580562
Protocol Number : ONC201-108
Phase : 3
Location : Saint John's Cancer Institute
Akanksha Sharma, M.D.

Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab (IORT)

NCT ID : 04681677
Protocol Number : CTPR-0017 GLIOX
Phase : 2
Location : Santa Monica, Ca
Naveed Wagle, M.D.

(TRIDENT) Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM (EF-32)

NCT ID : 04471844
Protocol Number : EF-32 Trident
Phase : N/A
Location : Saint John's Cancer Institute
Akanksha Sharma, M.D.

A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme (WHO Grade IV)

NCT ID : 04762069
Protocol Number : CNS-201
Phase : 2
Location : Saint John's Cancer Institute
Naveed Wagle, M.D.

Intermediate-size Expanded Access to ONC201 for Patients with H3 K27M-mutant and/or Midline Gliomas

NCT ID : 04617002
Protocol Number : ONC028
Phase : N/A
Location : Santa Monica, CA
Akanksha Sharma, M.D.

Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma

NCT ID : 04388475
Protocol Number : OKN-007
Phase : 2
Location : Santa Monica, CA
Santosh Kesari, M.D.

A First in Human Study To Evaluate the Safety and Tolerability of AdAPT-001 in Subjects With Refractory Solid Tumors (BETA-PRIME)

NCT ID : 04673942
Protocol Number : BETA PRIME
Phase : 1
Location : Santa Monica, CA
Akanksha Sharma, M.D.

Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209)

NCT ID : 03822117
Protocol Number : INCB 54828-209
Phase : 2
Location : Santa Monica, CA
Akanksha Sharma, M.D.